Effect of Pre‐Transplant Sensitization on Kidney Allograft Survival Following Simultaneous Liver and Kidney Transplantation: A Decade of Experience from an Academic Transplant Center
Clinical Transplantation · 2026
DOI: 10.1111/ctr.70656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2026. Verfasst von Andrew D Santeusanio und 10 weiteren Autor:innen. Beteiligte Einrichtung: Recanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Liver Transplantation, Histocompatibility Testing, Graft Survival. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
There are conflicting data regarding the impact of pre‐transplant sensitization on kidney allograft outcomes following simultaneous liver–kidney (SLK) transplantation.
Methods
This was a single‐center, retrospective study of adult SLK transplant recipients during the decade from 2010 to 2020. Patients were classified based on complement dependent cytotoxicity crossmatching (CDC‐CXM) as well as the presence of donor specific antibodies (DSA) and followed until study conclusion on January 1, 2021. Cox‐proportional hazards modeling was performed to identify clinical variables associated with combined patient and allograft survival as well as biopsy proven kidney rejection (BPAR).
Results
A total of 90 patients were included in the study (16 positive CDC‐CXM and 31 with DSA). Overall patient and allograft survival was 91.1% at 1‐year and 68.9% at study conclusion after a median of 4.4 years, with corresponding death‐censored kidney survival of 98.8% and 91.2%. In the multivariable analysis, a positive CDC‐CXM (HR = 3.79; 95% CI 1.70–8.46) but not pre‐formed DSA was associated with patient and graft loss. BPAR occurred in 12 patients (13.3%) and was higher among patients with DSA >5,000 (HR = 3.69; 95% CI 1.14–11.98), although this did not impact overall kidney survival. DSA cleared in 85% of patients following SLK transplant but persisted in three patients with DQ‐specific antibodies.
Conclusions
A positive CDC‐CXM but not the presence of pre‐formed DSA was associated with worse outcomes following SLK transplantation, with overall kidney survival primarily driven by death with a functioning allograft. DSA >5,000 MFI increased the risk for BPAR, and DSA to the class II DQ antigen were incompletely cleared following SLK transplant; however, overall kidney survival was not impacted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Recanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
- Department of Pharmacy, Mount Sinai Hospital, New York, New York, USA.
- Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Zitieren
APA
Santeusanio, A. D., Mahir, F., Facciuto, M., Shapiro, R., Delaney, V., Schiano, T., Moon, J., Florman, S., Kim-Schluger, L., Tedla, F., & Bhansali, A. (2026). Effect of Pre‐Transplant Sensitization on Kidney Allograft Survival Following Simultaneous Liver and Kidney Transplantation: A Decade of Experience from an Academic Transplant Center. Clinical Transplantation. https://doi.org/10.1111/ctr.70656
Vancouver
Santeusanio AD, Mahir F, Facciuto M, Shapiro R, Delaney V, Schiano T, et al. Effect of Pre‐Transplant Sensitization on Kidney Allograft Survival Following Simultaneous Liver and Kidney Transplantation: A Decade of Experience from an Academic Transplant Center. Clinical Transplantation. 2026. doi:10.1111/ctr.70656
BibTeX
@article{Santeusanio2026,
author = {Santeusanio, Andrew D and Mahir, Fahima and Facciuto, Matias and Shapiro, Ron and Delaney, Veronica and Schiano, Thomas and Moon, Jang and Florman, Sander and Kim-Schluger, Leona and Tedla, Fasika and Bhansali, Arjun},
title = {Effect of Pre‐Transplant Sensitization on Kidney Allograft Survival Following Simultaneous Liver and Kidney Transplantation: A Decade of Experience from an Academic Transplant Center},
journal = {Clinical Transplantation},
year = {2026},
doi = {10.1111/ctr.70656}
}
EUVIMED